# EDGAR Filing Document

**Accession Number:** 0001977769
**File Stem:** 0000950170-25-081739
**Filing Date:** 2025-6
**Character Count:** 10935
**Document Hash:** dd4678e6b848ce23623a9aa0e27dbc0c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-25-081739.hdr.sgml**: 20250604

**ACCESSION NUMBER**: 0000950170-25-081739

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250604

**DATE AS OF CHANGE**: 20250604

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Elicio Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001601485
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 113430072
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-93548
- **FILM NUMBER:** 251024010

**BUSINESS ADDRESS:**
- **STREET 1:** 451 D STREET, 5TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210
- **BUSINESS PHONE:** (857) 209-0050

**MAIL ADDRESS:**
- **STREET 1:** 451 D STREET, 5TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Angion Biomedica Corp.
- **DATE OF NAME CHANGE:** 20140228
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GKCC, LLC
- **CENTRAL INDEX KEY:** 0001977769

**ORGANIZATION NAME:**
- **EIN:** 472175589
- **STATE OF INCORPORATION:** DE

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 501 SILVERSIDE ROAD
- **STREET 2:** SUITE 87AVA
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19809
- **BUSINESS PHONE:** (302) 992-8882

**MAIL ADDRESS:**
- **STREET 1:** 501 SILVERSIDE ROAD
- **STREET 2:** SUITE 87AVA
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19809

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 6)**

**Elicio Therapeutics, Inc.**

*(Name of Issuer)*

**Common Stock, par value $0.01 per share**

*(Title of Class of Securities)*

**28657F103**

*(CUSIP Number)*

**GKCC, Incl**<br>501 Silverside Road<br>Suite 87AVA<br>Wilmington DE 19809<br>(302) 992-8882

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**06/03/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **28657F103** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**GKCC, LLC** | Name of reporting person<br>**GKCC, LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**—** | Source of funds (See Instructions)<br>**—** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**—** | Citizenship or place of organization<br>**—** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**9752139.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**9752139.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**9752139.00** | Aggregate amount beneficially owned by each reporting person<br>**9752139.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**48%** | Percent of class represented by amount in Row (11)<br>**48%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** Includes (a) 5,416,212 shares of Common Stock held directly by GKCC, LLC ("GKCC"), (b) 2,632,702 shares of Common Stock underlying Pre-Funded Warrants exercisable within 60 days, and (c) 1,703,225 shares of Common Stock underlying Common Warrants exercisable within 60 days. The shares are held of record by GKCC, LLC. Yekaterina Chudnovsky has sole voting and investment control over the shares held by GKCC, LLC and may be deemed to beneficially own such shares.

Percentage ownership is based on (a) 15,996,976 shares of Common Stock of the Issuer outstanding as of May 9, 2025, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the SEC on May 13, 2025, (b) 2,632,702 shares of Common Stock underlying Pre-Funded Warrants exercisable within 60 days and (d) 1,703,225 shares of Common Stock underlying Common Warrants exercisable within 60 days.

| **CUSIP No.** | **28657F103** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Yekaterina Chudnovsky** | Name of reporting person<br>**Yekaterina Chudnovsky** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**—** | Source of funds (See Instructions)<br>**—** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**—** | Citizenship or place of organization<br>**—** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**9764864.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**9764864.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**9764864.00** | Aggregate amount beneficially owned by each reporting person<br>**9764864.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**48%** | Percent of class represented by amount in Row (11)<br>**48%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** Consists of (a) 12,725 shares of the common stock, par value $0.01 per share ("Common Stock") of Elicio Therapeutics, Inc. (the "Issuer"), (b) 5,416,212 shares of Common Stock held directly by GKCC, LLC ("GKCC"), (c) 2,632,702 shares of Common Stock underlying pre-funded warrants ("Pre-Funded Warrants") exercisable within 60 days, and (d) 1,703,225 shares of Common Stock underlying common warrants ("Common Warrants") exercisable within 60 days.

Percentage ownership is based on (a) 15,996,976 shares of Common Stock of the Issuer outstanding as of May 9, 2025, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the SEC on May 13, 2025, (b) 2,632,702 shares of Common Stock underlying Pre-Funded Warrants exercisable within 60 days and (c) 1,703,225 shares of Common Stock underlying Common Warrants exercisable within 60 days.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.01 per share

**(b) Name of Issuer:**
Elicio Therapeutics, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
451 D Street, 5th Floor, Suite 501, Boston, MA, 02210

This Amendment No. 6 ("Amendment") amends and supplements the Statement on Schedule 13D originally filed with the Securities and Exchange Commission (the "SEC") on June 14, 2023 (as amended to date, the "Original Statement"), which relates to the shares of common stock, par value $0.01 per share (the "Common Stock"), of Elicio Therapeutics, Inc. (the "Issuer"). Except as otherwise described herein, the information contained in the Original Statement remains in effect.

**Item 4. Purpose of Transaction**

Item 4 is hereby amended and supplemented as follows:

The response to Item 3 of this Schedule 13D is incorporated by reference herein.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Item 5 is hereby amended and supplemented as follows:

(a, b) The information set forth in rows 7 through 13 of the cover pages to this Schedule 13D is incorporated by reference. As of the date of this Schedule 13D, Ms. Chudnovsky may be deemed to beneficially own, in the aggregate, 9,764,864shares of Common Stock, which represents approximately 48.0% of the shares of Common Stock outstanding.

Ms. Chudnovsky's beneficial ownership consists of (i) 12,725 shares of Common Stock held directly by Ms. Chudnovsky, (ii) 5,416,212 shares of Common Stock held directly by GKCC, LLC, (iii) 2,632,702 shares of Common Stock underlying Pre-Funded Warrants exercisable within 60 days, and (iv) 1,703,225 shares of Common Stock underlying Common Warrants exercisable within 60 days.

The foregoing beneficial ownership percentages are based upon (i) a total of 15,996,976 shares of Common Stock of the Issuer outstanding as of May 9, 2025, as reported by the Issuer in its Quarterly Report on Form 10-Q as filed with the SEC on May 13, 2025, (ii) 2,632,702 shares of Common Stock underlying Pre-Funded Warrants exercisable within 60 days and (iii) 1,703,225 shares of Common Stock underlying Common Warrants exercisable within 60 days.

(c) The response to Item 3 is incorporated by reference herein. Except as set forth in this Schedule 13D, no transactions in the shares of Common Stock have been effected by the Reporting Persons within the past 60 days.

**(b)**
—

**(c)**
—

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Item 6 is hereby amended and supplemented as follows:

The response to Item 3 of this Schedule 13D is incorporated by reference herein.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** GKCC, LLC

**Signature:** /s/ Yekaterina Chudnovsky

**Name/Title:** Yekaterina Chudnovsky, Manager

**Date:** 06/04/2025